We are live on
!
Find out more
RCM
RA Capital Management Portfolio holdings
AUM
$9.44B
1-Year Est. Return
157.3%
This Fund
S&P 500
This Quarter
Est. Return
+7.43%
1 Year Est. Return
+157.3%
3 Year Est. Return
+589.39%
5 Year Est. Return
+654.96%
10 Year Est. Return
+50,915.53%
AUM
$994M
AUM Growth
-$12.8M
(-1.3%)
Cap. Flow
-$17.3M
Cap. Flow
% of AUM
-1.74%
Top 10 Holdings %
Top 10 Hldgs %
57.44%
Holding
72
New
15
Increased
6
Reduced
13
Closed
13
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
SIOX
Sio Gene Therapies Inc. Common Stock
SIOX
|
+$106M |
| 2 |
Collegium Pharmaceutical
COLL
|
+$26.7M |
| 3 |
BPMC
Blueprint Medicines
BPMC
|
+$25.1M |
| 4 |
Ardelyx
ARDX
|
+$21.7M |
| 5 |
MDCO
Medicines Co
MDCO
|
+$19.7M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
BioCryst Pharmaceuticals
BCRX
|
+$49.1M |
| 2 |
Arbutus Biopharma
ABUS
|
+$47.4M |
| 3 |
DVAX
Dynavax Technologies
DVAX
|
+$39.9M |
| 4 |
DYAX
DYAX CORPORATION
DYAX
|
+$39.9M |
| 5 |
Larimar Therapeutics
LRMR
|
+$29M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 75.93% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
SIOX
1
DELISTED
Sio Gene Therapies Inc. Common Stock
SIOX
| $102M | 10.25% |
+625,000
| New | +$106M |
|
|
ACHN
2
DELISTED
Achillion Pharmaceuticals
ACHN
| $88.1M | 8.86% |
9,945,997
+1,738,467
| +21% | +$16.4M |
|
|
DYAX
3
DELISTED
DYAX CORPORATION
DYAX
| $71.6M | 7.21% |
2,703,093
-1,504,501
| -36% | -$39.9M |
|
|
SGMO
4
CALL
DELISTED
SANGAMO THERAPEUTICS INC
SGMO
| $66.5M | 6.69% |
6,000,000
| – | – |
|
5
TG Therapeutics
TGTX
$8.19B
| $54.8M | 5.51% |
3,302,213
+177,064
| +6% | +$2.8M |
|
|
RGLS
6
DELISTED
Regulus Therapeutics
RGLS
| $41.5M | 4.18% |
31,587
+1,665
| +6% | +$2.69M |
|
7
Coherus Oncology
CHRS
$217M
| $39.9M | 4.01% |
1,380,320
-175,035
| -11% | -$4.42M |
|
|
8
BioCryst Pharmaceuticals
BCRX
$2.42B
| $38.9M | 3.91% |
2,605,361
-4,321,256
| -62% | -$49.1M |
|
|
DRNA
9
DELISTED
Dicerna Pharmaceuticals, Inc.
DRNA
| $33.9M | 3.41% |
2,428,571
| – | – |
|
10
Ascendis Pharma A/S
ASND
$16.5B
| $33.8M | 3.4% |
1,913,153
+889,501
| +87% | +$15.6M |
|
|
11
Collegium Pharmaceutical
COLL
$1.18B
| $27.6M | 2.77% |
+1,545,410
| New | +$26.7M |
|
|
12
Ardelyx
ARDX
$1.24B
| $27.5M | 2.76% |
+1,719,945
| New | +$21.7M |
|
13
Protara Therapeutics
TARA
$214M
| $26.9M | 2.71% |
37,672
+6,422
| +21% | +$3.97M |
|
14
Xencor
XNCR
$1.45B
| $23.6M | 2.38% |
1,075,410
-1,074,013
| -50% | -$18.3M |
|
|
BPMC
15
DELISTED
Blueprint Medicines
BPMC
| $23.3M | 2.34% |
+878,348
| New | +$25.1M |
|
|
BLCM
16
DELISTED
Bellicum Pharmaceuticals, Inc.
BLCM
| $21.8M | 2.2% |
102,640
| – | – |
|
|
MDCO
17
DELISTED
Medicines Co
MDCO
| $20.2M | 2.03% |
+705,925
| New | +$19.7M |
|
|
BLUE
18
DELISTED
bluebird bio
BLUE
| $18.4M | 1.85% |
8,444
-7,025
| -45% | -$14.3M |
|
|
DVAX
19
DELISTED
Dynavax Technologies
DVAX
| $17.9M | 1.81% |
766,000
-1,834,000
| -71% | -$39.9M |
|
|
CDTX
20
DELISTED
Cidara Therapeutics
CDTX
| $16M | 1.61% |
+57,067
| New | +$17.6M |
|
21
Novavax
NVAX
$1.21B
| $15.9M | 1.6% |
71,562
| – | – |
|
|
JUNO
22
DELISTED
Juno Therapeutics, Inc.
JUNO
| $14.9M | 1.5% |
280,000
| – | – |
|
|
AGEN
23
Agenus
AGEN
$276M
| $13.8M | 1.39% |
+81,520
| New | +$11.6M |
|
|
SGMO
24
DELISTED
SANGAMO THERAPEUTICS INC
SGMO
| $13.5M | 1.36% |
1,220,209
| – | – |
|
25
Omeros
OMER
$845M
| $13.5M | 1.36% |
749,000
| – | – |
|
Similar funds
RCMNY
SCM
SIM
NPT
AC
PVI
WPL
BAMF
RA Capital Management's Q2 2015 Portfolio in Review
As of Q2 2015, RA Capital Management held 72 positions worth $994M, down 1.3% from $1.01B the previous quarter. Its ten largest holdings account for 57% of the portfolio.
RA Capital Management's Q2 2015 filing shows 15 new, 6 increased, 13 reduced and 13 closed positions. Its largest new stake was Sio Gene Therapies Inc. Common Stock: 625,000 shares worth $102M. The largest sale was BioCryst Pharmaceuticals, an estimated $49.1M.
By sector, the portfolio is most concentrated in Healthcare at 76% of assets, up from 70% a quarter earlier.
- RA Capital Management's largest Q2 2015 buy was Sio Gene Therapies Inc. Common Stock: 625,000 shares worth $102M.
- RA Capital Management added most to Achillion Pharmaceuticals in Q2 2015, an estimated $16.4M increase.
- RA Capital Management's biggest Q2 2015 reduction was BioCryst Pharmaceuticals, cutting an estimated $49.1M.
- RA Capital Management fully exited Arbutus Biopharma in Q2 2015, selling an estimated $47.4M.
- RA Capital Management's ten largest holdings make up 57% of its $994M portfolio in Q2 2015.
- RA Capital Management opened 15 new positions and closed 13 in Q2 2015.
- RA Capital Management's portfolio value fell 1.3% quarter-over-quarter to $994M.
Based on RA Capital Management's 13F filing for Q2 2015, filed 13 Aug 2015.